Global Markets Direct’s, ‘Liver Failure – Pipeline Review, H2 2015′, provides an overview of the Liver Failure’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Failure and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Liver Failure
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Liver Failure and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Liver Failure pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Liver Failure
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Liver Failure pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liver Failure Overview 7
Therapeutics Development 8
Pipeline Products for Liver Failure - Overview 8
Pipeline Products for Liver Failure - Comparative Analysis 9
Liver Failure - Therapeutics under Development by Companies 10
Liver Failure - Therapeutics under Investigation by Universities/Institutes 11
Liver Failure - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Liver Failure - Products under Development by Companies 16
Liver Failure - Products under Investigation by Universities/Institutes 17
Liver Failure - Companies Involved in Therapeutics Development 18
Alfact Innovation 18
Cell2B S.A. 19
Conatus Pharmaceuticals Inc. 20
Digna Biotech, S.L. 21
Immune Pharmaceuticals Inc. 22
Silence Therapeutics Plc 23
Ventria Bioscience 24
Liver Failure - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
ALF-5755 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Cardiotrophin-1 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Cell Therapy for Liver Failure - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
emricasan - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
F-573 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GRI-0621 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Hep-114 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ImmuneSafe - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Oligonucleotide for Liver Failure - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
RNAi Oligonucleotide for Liver Diseases - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
RNAi Oligonucleotides to Inhibit MAP Kinase 4 for Liver Failure - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure, Post Cardiopulmonary Resuscitation and Neurodegenerative Diseases - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
VEN-100 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Liver Failure - Recent Pipeline Updates 56
Liver Failure - Dormant Projects 62
Liver Failure - Discontinued Products 63
Liver Failure - Product Development Milestones 64
Featured News & Press Releases 64
Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 64
Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 66
Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 66
Apr 02, 2013: ALF-5755 phase II completion 67
Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure 67
Sep 21, 2011: Digna Biotech Receives FDA Orphan Drug Status For Cardiotrophin-1 For Acute Liver Failure Treatment 68
May 06, 2011: ALF-5755 phase II extends to germany 69
May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA 69
Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 69
Mar 10, 2011: Digna Biotech And Biotecnol Announce Spanish Approval For Phase I Clinical study Of Cardiotrophin I 69
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 71
Disclaimer 72

List of Tables

Number of Products under Development for Liver Failure, H2 2015 8
Number of Products under Development for Liver Failure - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Comparative Analysis by Unknown Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Products under Investigation by Universities/Institutes, H2 2015 17
Liver Failure - Pipeline by Alfact Innovation, H2 2015 18
Liver Failure - Pipeline by Cell2B S.A. , H2 2015 19
Liver Failure - Pipeline by Conatus Pharmaceuticals Inc., H2 2015 20
Liver Failure - Pipeline by Digna Biotech, S.L., H2 2015 21
Liver Failure - Pipeline by Immune Pharmaceuticals Inc., H2 2015 22
Liver Failure - Pipeline by Silence Therapeutics Plc, H2 2015 23
Liver Failure - Pipeline by Ventria Bioscience, H2 2015 24
Assessment by Monotherapy Products, H2 2015 25
Number of Products by Stage and Target, H2 2015 27
Number of Products by Stage and Mechanism of Action, H2 2015 29
Number of Products by Stage and Route of Administration, H2 2015 31
Number of Products by Stage and Molecule Type, H2 2015 33
Liver Failure Therapeutics - Recent Pipeline Updates, H2 2015 56
Liver Failure - Dormant Projects, H2 2015 62
Liver Failure - Discontinued Products, H2 2015 63

List of Figures

Number of Products under Development for Liver Failure, H2 2015 8
Number of Products under Development for Liver Failure - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Products, H2 2015 14
Assessment by Monotherapy Products, H2 2015 25
Number of Products by Top 10 Targets, H2 2015 26
Number of Products by Stage and Top 10 Targets, H2 2015 26
Number of Products by Top 10 Mechanism of Actions, H2 2015 28
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 28
Number of Products by Routes of Administration, H2 2015 30
Number of Products by Stage and Routes of Administration, H2 2015 30
Number of Products by Top 10 Molecule Types, H2 2015 32
Number of Products by Stage and Top 10 Molecule Types, H2 2015 32